Persistent SIX2 expression as a first hit mechanism in Wilms tumorigenesis
Persistent SIX2 expression as a first hit mechanism in Wilms tumorigenesis
批准号:
9248187
负责人:
Harold Newton Lovvorn
金额:
$3.36万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-12-01 至 2017-05-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Wilms tumor (WT) is a pediatric renal malignancy thought to arise from persistence and aberrant differentiation of embryonic kidney stem cells. Precisely how nephron progenitors escape pathways of epithelial commitment and conversion, mechanisms that potentially represent "first hits" in Wilms tumorigenesis, have not been clarified. WT blastema, the putative malignant analogue of these nephron progenitors, retains expression of the transcriptional regulator, SIX2, which in mouse development promotes self-renewal of the cap mesenchyme (CM) and prevents premature epithelial differentiation. Our previous work has shown that SIX2, normally absent in the adult kidney, is persistently expressed across a broad spectrum of human WT. Putting together these observations of SIX2 activity in development and disease, the fundamental question arises whether this gene provides a mechanism for the CM and its progeny to self-perpetuate in the WT sequence. The purpose of developing this mouse model is to test the hypothesis that persistent expression of SIX2 in the CM impairs epithelial differentiation, and promotes retention of this progenitor population and development of nephrogenic rests, the putative precursor lesion of WT. We have two aims: 1) To generate and validate a tetracycline-regulated transgenic mouse line that allows temporal control of SIX2 expression in the embryonic kidney, and 2) To characterize the phenotype of persistent SIX2 expression in the embryonic and adult kidney. A founder transgenic mouse line will be engineered to express SIX2 persistently under the control of a tetracycline response element (TRE-RFP-2A-SIX2). Once validated, this mouse will be crossed with the ROSA26-M2-rtTA line, which provides global and constitutive expression of rtTA (Tet-On). Doxycycline will be administered to dams at e15.5 to activate SIX2 transgene expression, and its effects on CM differentiation and persistence will be evaluated. Persistence of CM cells within the post-natal kidney resembling nephrogenic rests is the anticipated phenotype. These pilot studies will lay the foundation for future, more definitive investigation targeting persisten SIX2 expression to the CM only. These future studies will use the CM-specific CITED1-Cre-ERT2 mouse engineered previously in our laboratory.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Persistent SIX2 expression as a first hit mechanism in Wilms tumorigenesis
-
批准号:8812986
-
项目类别:
-
资助金额:$4.46万
-
财政年份:2014
-
负责人:Harold Newton Lovvorn
-
依托单位:
Persistent SIX2 expression as a first hit mechanism in Wilms tumorigenesis
-
批准号:8976148
-
项目类别:
-
资助金额:$7.9万
-
财政年份:2014
-
负责人:Harold Newton Lovvorn
-
依托单位:
MolecularAnalysis of Ethnic Variations in Wilms' Tumor
-
批准号:8191920
-
项目类别:
-
资助金额:$20.54万
-
财政年份:2011
-
负责人:Harold Newton Lovvorn
-
依托单位:
MolecularAnalysis of Ethnic Variations in Wilms' Tumor
-
批准号:8335428
-
项目类别:
-
资助金额:$17.18万
-
财政年份:2011
-
负责人:Harold Newton Lovvorn
-
依托单位:
CITED1 nuclear localization and its role in Wilms' tumor pathogenesis
-
批准号:8122503
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2008
-
负责人:Harold Newton Lovvorn
-
依托单位:
CITED1 nuclear localization and its role in Wilms' tumor pathogenesis
-
批准号:7687380
-
项目类别:
-
资助金额:$12.73万
-
财政年份:2008
-
负责人:Harold Newton Lovvorn
-
依托单位:
CITED1 nuclear localization and its role in Wilms' tumor pathogenesis
-
批准号:8309471
-
项目类别:
-
资助金额:$24.15万
-
财政年份:2008
-
负责人:Harold Newton Lovvorn
-
依托单位:
CITED1 nuclear localization and its role in Wilms' tumor pathogenesis
-
批准号:7513109
-
项目类别:
-
资助金额:$12.73万
-
财政年份:2008
-
负责人:Harold Newton Lovvorn
-
依托单位:
CITED1 nuclear localization and its role in Wilms' tumor pathogenesis
-
批准号:8132565
-
项目类别:
-
资助金额:$24.15万
-
财政年份:2008
-
负责人:Harold Newton Lovvorn
-
依托单位:
国内基金
海外基金
登录
查看更多内容
lncRNA MYCNOS编码多肽MYCNOSDP调控SIX2影响肾母细胞瘤增殖的作用机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:王智
-
依托单位:
SIX2通过DDIT4调控mTOR-细胞自噬信号促进帕金森病小胶质细胞极化的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:
-
依托单位:
KPNB1靶向调控转录因子Six2入核及泛素化在肾癌发生发展中的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:宋涛
-
依托单位:
Six2调控DNMT1表观遗传修饰E-cadherin在肝癌上皮间质转化及化疗耐药 中的作用及机制研究
-
批准号:82060550
-
项目类别:地区科学基金项目
-
资助金额:34.0万元
-
批准年份:2020
-
负责人:李建旺
-
依托单位:
Six2调控DNMT1表观遗传修饰E-cadherin在肝癌上皮间质转化及化疗耐药 中的作用及机制研究
-
批准号:--
-
项目类别:--
-
资助金额:34万元
-
批准年份:2020
-
负责人:李建旺
-
依托单位:
转录调控因子SIX2在前列腺癌神经内分泌转化中的分子机制与靶向研究
-
批准号:--
-
项目类别:--
-
资助金额:100万元
-
批准年份:2020
-
负责人:尚芝群
-
依托单位:
转录因子Six1/Six2通过BMP信号通路调控上下颌突铰链区发育在颌骨黏连发生中的作用机制
-
批准号:82071096
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:王旭东
-
依托单位:
长链非编码RNA LINC01883通过募集转录因子SRF上调SIX2表达促进胃癌干细胞的自我更新和化疗耐药的机制
-
批准号:82073381
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:张家兴
-
依托单位:
Akt1\Eya1\Six2信号通路介导GDNF应激性表达在多巴胺能神经细胞变性修复中的作用机制研究
-
批准号:81901299
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:高锦
-
依托单位:
转录因子Six2通过假基因CYP4Z2P介导的ceRNA网络调控乳腺癌对阿霉素耐药性的机制研究
-
批准号:81702957
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:郑禄枫
-
依托单位: